Compare Toronto-Dominion Bank (TD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs GeneDx Holdings Corp — how do they compare? Toronto-Dominion Bank trades at $120.58 (market cap $197.03B), while GeneDx Holdings Corp trades at $60.8 (market cap $1.80B). The key difference: Toronto-Dominion Bank is far larger — about 109.5× GeneDx Holdings Corp's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TD | WGS | |
|---|---|---|
Market Cap | $197.03B | $1.80B |
Sector | Financials | Technology |
52-Week High | $124.80 | $167.51 |
52-Week Low | $72.55 | $34.51 |
Dividend Yield | 2.62% | — |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $120.56, down 2.46% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.74 exceeding the $1.63 estimate. Revenue growth remains steady, increasing from $56.3B in 2024 to $61.3B in 2025, while net income margin improved significantly to 33.51%.
Analyst consensus is bullish with a $153 price target representing 27% upside potential. Key risks include volatile cash flow patterns and high debt levels, while opportunities lie in continued earnings outperformance and dividend stability. The stock presents a compelling value proposition for investors seeking banking sector exposure with growth potential.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
